Pheochromocytoma/paraganglioma: clinical and genetic aspects

Iukina M.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Troshina E.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Bel'tsevich D.G.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Tiul'pakov A.N.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Lysenko M.A.

Gorodskaia klinicheskaia bol'nitsa #52, Moskva

Pheochromocytoma/paraganglioma: clinical and genetic aspects

Authors:

Iukina M.Iu., Troshina E.A., Bel'tsevich D.G., Tiul'pakov A.N., Lysenko M.A.

More about the authors

Journal: Problems of Endocrinology. 2013;59(3): 19‑26

Downloaded: 74

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Iukina MIu, Troshina EA, Bel'tsevich DG, Tiul'pakov AN, Lysenko MA. Pheochromocytoma/paraganglioma: clinical and genetic aspects. Problems of Endocrinology. 2013;59(3):19‑26. (In Russ.)

Close metadata

Recommended articles:

Simultaneous occurrence of facial neurinoma in internal auditory canal and middle ear paraganglioma in patient. Unusual combination and difficult surgical task. Russian Bulletin of Otorhinolaryngology. 2024;(3):69-76

Difficulties of diagnosing a clinically silent pheochromocytoma. Russian Journal of Preventive Medicine. 2025;(3):107-111

The present retrospective descriptive and analytical study included 167 patients divided into three groups. Two groups were comprised of the patients with genetically predetermined pheochromocytoma (type 2 MEN syndrome and von Hippel-Lindau disease respectively), the third croup consisted of the patients presenting with sporadic pheochromocytoma. The median age at which pheochromocytoma was diagnosed was 25 years in group 1, 18 years in group 2, and 47 years in group 3. Adrenalin-type secretion was predominated in group 1 in contrast to the noradrenalin-type and mixed-type secretion in the patients of groups 2 and 3 respectively. The patients of group 1 showed positive correlation between the tumour size and excretion of methylated catecholamines. 82% of these patients exhibited bilateral adrenal lesions and 58% suffered multifocal lesions; no cases of extra-adrenal localization of the tumour were documented. The extra-adrenal localization of pheochromocytomas was observed in 16.4% of the patients in group 2, where 6.6% of the patients had metastases. No metastases of pheochromocytoma were found in the patients of groups 1 and 3. It is concluded that the patients under the age of 40 presenting with bilateral and multicentral pheochromocytoma with the aggravated familial history need the genetic predetermination of the disease to be excluded taking into account syndromal symptoms. Examination for the detection of type 2 MEN is not required in the patients showing isolated normetanephrin excretion. Nor is the search for metastases of pheochromocytoma and its extra-adrenal localization is necessary in the patients presenting with type 2 MEN syndrome and/or exhibiting isolated metanephrin excretion.

Keywords:

pheochromocytoma

paraganglioma

Hippel-Lindau disease

type 2 multiple endocrine neoplasia

catecholamines

Authors:

Iukina M.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Troshina E.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Bel'tsevich D.G.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Tiul'pakov A.N.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Lysenko M.A.

Gorodskaia klinicheskaia bol'nitsa #52, Moskva

List of references:

Amar L. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005; 23: 8812-8818.
Benn D.E., Gimenez-Roqueplo A.P., Reilly J.R., Bertherat J., Burgess J., Byth K., Croxson M., Dahia P.L., Elston M., Gimm O., Henley D., Herman P., Murday V., Niccoli-Sire P., Pasieka J.L., Rohmer V., Tucker K., Jeunemaitre X., Marsh D.J., Plouin P.F., Robinson B.G. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metabol 2006; 91: 790-836.
Jiménez C., Cote G., Arnold A., Gagel R.F. Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metabol 2006; 91: 2851-2858.
Yip L., Lee J.E., Shapiro S.E., Waguespack S.G., Sherman S.I., Hoff A.O., Gagel R.F., Arens J.F., Evans D.B. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 2004; 198: 525-535.
John H., Ziegler W.H., Hauri D., Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 1999; 3: 679-683.
Klingler H.C., Klingler P.J., Martin J.K. Jr., Smallridge R.C., Smith S.L., Hinder R.A. Pheochromocytoma. Urology 2001; 57: 1025-1032.
Graff J.W. VHL. Family Forum, Newsletter of the VHL Family Alliance and the Cancer Research Fund. VHL 2009; 17.
Frank-Raue K., Machens A., Scheuba C., Niederle B., Dralle H., Raue F. Difference in the development of medullary thyroid carcinoma among carriers of RET mutations in codon 790 and 791. Clin Endocrinol 2008; 69: 259-263.
Modigliani E., Cohen R., Campos J.M., Conte-Devolx B., Maes B., Boneu A., Schlumberger M., Bigorgne J.C., Dumontier P., Leclerc L., Corcuff B., Guilhem I. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma, results in 899 patients. Clin Endocrinol 1998; 48: 265-273.
Szinnai G., Meier C., Komminoth P., Zumsteg U.W. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 2003; 111: 132-139.
Schuffenecker I., Virally-Monod M., Brohet R., Goldgar D., Conte-Devolx B., Leclerc L., Chabre O., Boneu A., Caron J., Houdent C., Modigliani E., Rohmer V., Schlumberger M., Eng C., Guillausseau P.J., Lenoir G.M. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metabol 1998; 83: 487-491.
Kloos R.T., Eng C., Evans D.B., Francis G.L., Gagel R.F., Gharib H., Moley J.F., Pacini F., Ringel M.D., Schlumberger M., Wells S.A. Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565-612.
Pacak K., Linehan W.M., Eisenhofer G., Walther M.M., Goldstein D.S. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134: 315-329.
Barontini M., Levin G., Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci 2006; 1073: 30-37.
Manger W.M. The vagaries of pheochromocytomas. Am J Hypertens 2005; 18: 1266-1270.
Pacak K., Lenders J.W.M., Eisenhofer G. Catecholamines and adrenergic receptors. In: pheochromocytoma: diagnosis, localization and treatment. Malden MA: Blackwell 2007; 41-71.
Eisenhofer G., Walther M.M., Huynh T.T., Li S.T., Bornstein S.R., Vortmeyer A., Mannelli M., Goldstein D.S., Linehan W.M., Lenders J.W., Pacak K. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metabol 2001; 86: 1999-2008.
Kaltsas G.A., Papadogias D., Makras P., Grossman A.B. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocrinol Relat Cancer 2005; 12: 683-699.
Pacak K., Lenders J.W.M., Eisenhofer G. Introduction. In: pheochromocytoma diagnosis, localization and treatment. Malden MA: Blackwell 2007; 1-2.
DeLellis R.A., Lloyd R.V., Heitz P.U., Eng C. WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press 2004; 147-150.

Close metadata